1.77
Precedente Chiudi:
$1.69
Aprire:
$1.72
Volume 24 ore:
137.18K
Relative Volume:
0.90
Capitalizzazione di mercato:
$8.10M
Reddito:
$895.50K
Utile/perdita netta:
$-26.30M
Rapporto P/E:
-1.0793
EPS:
-1.64
Flusso di cassa netto:
$-23.84M
1 W Prestazione:
+23.78%
1M Prestazione:
-10.61%
6M Prestazione:
-70.70%
1 anno Prestazione:
-86.17%
Mainz Biomed N V Stock (MYNZ) Company Profile
Nome
Mainz Biomed N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MYNZ con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MYNZ
Mainz Biomed N V
|
1.77 | 7.74M | 895.50K | -26.30M | -23.84M | -1.64 |
![]()
TMO
Thermo Fisher Scientific Inc
|
489.01 | 183.16B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
210.93 | 150.53B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
650.84 | 52.32B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
119.20 | 33.77B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
191.09 | 32.20B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-14 | Iniziato | Maxim Group | Buy |
2024-11-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
2023-11-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2022-06-21 | Iniziato | H.C. Wainwright | Buy |
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Can Mainz Biomed N.V. navigate macro headwindsRate Cut & Target Return Focused Stock Picks - thegnnews.com
Why Mainz Biomed N.V. stock attracts strong analyst attention2025 Retail Activity & Community Consensus Trade Alerts - beatles.ru
What are Mainz Biomed N.V.’s recent SEC filings showing2025 Market Sentiment & Risk Controlled Swing Alerts - sundaytimes.kr
Is Mainz Biomed N.V. a speculative investmentJuly 2025 PreEarnings & AI Powered Buy/Sell Recommendations - newsyoung.net
Mainz Biomed Wins Swiss Regulatory Approval for Colorectal Cancer Screening Test - MarketScreener
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval By Investing.com - Investing.com South Africa
Mainz Biomed’s colorectal cancer test receives Swiss regulatory approval - Investing.com
Mainz Biomed N.V. Receives Swiss Regulatory Approval to Market ColoAlert - MarketScreener
Is Mainz Biomed N.V. stock reversal real or fakeShort-Term Profit Alert With Entry Forecast - Newser
Mainz Biomed Secures $3 Million Through Securities Purchase Agreement - The Globe and Mail
Mainz Biomed Secures $3 Million in Funding Through Securities Purchase Agreement - AInvest
Mainz Biomed Prices $3 million Follow-on Offering at $1.35 per Unit - MarketScreener
Mainz Biomed raises $3M in follow-on offering. - AInvest
Mainz Biomed Prices $3.0M Follow-On Offering of Over 2.2M Units Including Ordinary Shares and Series A Warrants - 富途牛牛
Mainz Biomed Raises $3M in Follow-On Offering, Expects to Close on August 5 - AInvest
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
What is Mainz Biomed N.V. company’s growth strategySuperior portfolio returns - Jammu Links News
Should I hold or sell Mainz Biomed N.V. stock in 2025Achieve rapid capital gains with smart investing - Jammu Links News
Is Mainz Biomed N.V. stock overvalued or undervaluedGet alerts on high-potential market moves - Jammu Links News
What institutional investors are buying Mainz Biomed N.V. stockGet real-time updates on market movers - Jammu Links News
What is the risk reward ratio of investing in Mainz Biomed N.V. stockSkyrocketing returns - Jammu Links News
Why is Mainz Biomed N.V. stock attracting strong analyst attentionBuild wealth steadily with proven investment strategies - Jammu Links News
How does Mainz Biomed N.V. compare to its industry peersGet alerts on the hottest market movers - Jammu Links News
What is the dividend policy of Mainz Biomed N.V. stockRapid return acceleration - Jammu Links News
Does Mainz Biomed N.V. stock perform well during market downturnsTremendous return on equity - Jammu Links News
How strong is Mainz Biomed N.V. company’s balance sheetUnprecedented growth rates - Jammu Links News
What catalysts could drive Mainz Biomed N.V. stock higher in 2025Capitalize on market trends with confidence - Jammu Links News
How many analysts rate Mainz Biomed N.V. as a “Buy”Advanced Screener Planner For 2025 - Jammu Links News
Mainz Biomed Announces Sale of 1.47 Million Ordinary Units to Bolster Financial Position and Support Growth Initiatives - AInvest
What are Mainz Biomed N.V. company’s key revenue driversDaily Trading Outlook With Proven Results - Jammu Links News
Chartists See Breakout Potential in Mainz Biomed N.V.Real Trader Watchlist of Hot Stocks Released - metal.it
What are the technical indicators suggesting about Mainz Biomed N.V.Stay ahead with advanced stock screening tools - Jammu Links News
What institutions are buying Mainz Biomed N.V. stock nowFree Stock Market Beginners Guide - metal.it
Mainz Biomed N.V. Stock Analysis and ForecastStrong return on assets - Jammu Links News
Does Mainz Biomed N.V. stock pay reliable dividendsRapid capital growth - Jammu Links News
Mainz Biomed N V Azioni (MYNZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):